The youngest participants DBV Technologies has ever enrolled in a peanut allergy trial are no older than 12 months — and that developmental window is precisely why THRIVE‘s design is worth scrutinizing. The Phase 2 study, which screened its first participant in Ontario last week, targets infants ages 6 through 12 months with confirmed peanut allergy, pushing the VIASKIN epicutaneous patch into an age cohort where immune plasticity is highest and where an intervention, if effective, could theoretically redirect allergic trajectory before it becomes entrenched. The clinical logic is sound; the execution demands are considerable.
THRIVE is a single-arm, open-label study — no placebo comparison — with a primary endpoint defined as ad lib peanut consumption, meaning unrestricted intake as much and as often as desired. Participants wear the patch daily for 36 months on a strict peanut-free diet, then face a food challenge at month 36 that determines whether they enter a 12-month dietary integration period with or without continued patching. The total study duration runs to 48 months. That four-year commitment, in a population that will be kindergarten-aged by study completion, creates real retention risk, and the open-label design means efficacy signals will need to be interpreted carefully against the absence of a control arm.
The strategic rationale builds directly on positive Phase 2 and Phase 3 data DBV generated in toddlers aged 1–3 and children aged 4–7. Those cohorts de-risked the basic safety and tolerability profile in young skin. Infants present a different biological and practical proposition — thinner skin, higher surface-area-to-body-weight ratios, and caregivers managing patch adherence around the clock. The ad lib endpoint, defined through prespecified criteria combining single-sitting intake, longitudinal consumption patterns, and caregiver-reported outcomes, is more ambitious than the threshold-based desensitization endpoints common in oral immunotherapy trials. That ambition raises the scientific stakes but also the commercial narrative if results hold.
The single number that matters most as THRIVE progresses is the 36-month food challenge pass rate — not the proportion reaching any peanut tolerance, but specifically those who sustain ad lib consumption through months 37–48 without continued patching. That subset will define whether epicutaneous immunotherapy in infancy produces durable immune modification or simply maintained suppression.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
